OKLAHOMA CITY, Sept. 4, 2013 (GLOBE NEWSWIRE) -- Protea Biosciences Group, Inc. (the "Company" or "Protea") announced today that the University of Oklahoma's Institute for Natural Products Applications and Research Technologies (INPART) has acquired the LAESI DP1000 biomolecular imaging system. INPART is directed by Robert Cichewicz, Ph.D., associate professor in the Department of Chemistry and Biochemistry. INPART intends to use the instrument for its natural products-based drug discovery operations.
Cichewicz plans to use this new instrument to characterize newly discovered compounds produced by fungi and other microbes, in an effort to develop new treatments for life-threatening infections.
LAESI (short for Laser Ablation Electrospray Ionization) is designed to rapidly generate imaging profiles of the biomolecules present in cells and to analyze tissue sections identical to those used in pathology. The LAESI DP-1000 is intended to allow the direct identification of biomolecules in living cells and bacterial colonies, with analysis completed in seconds to minutes. Thus, molecular changes that occur in cells over time can be identified and tracked.
Cichewicz said, "This instrument is designed to allow us to examine the changes that occur in fungal and bacterial colonies such as their production of secondary metabolites, permitting us to identify and characterize new candidate antimicrobial compounds."
INPART studies microbial natural products, which are the unique compounds produced by fungi and bacteria. These compounds play important roles in helping microorganisms adapt to their environment, and they exhibit a diverse array of novel structures. INPART focuses on using secondary metabolites from fungi and bacteria for the treatment of human diseases such as life-threatening infections and cancer.
The LAESI DP-1000, developed by Protea, received the 2012 R&D 100 Award, and was selected by an independent judging panel and the editors of R&D Magazine as one of the 100 most technologically significant products introduced in 2012.
About Protea Biosciences Group, Inc.
Protea is a technology leader in the field of mass spectrometry ("mass spec") molecular imaging - the identification and localization of the molecular products of living cells, that is foundational science for all pharmaceutical, medical, and life science research.
Protea website: www.proteabio.com
About LAESI: https://proteabio.com/LAESI
This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions are forward-looking statements. All forward-looking statements involve risks, uncertainties and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements, as described in our reports filed with the Securities and Exchange Commission which are available for review at www.sec.gov, to differ materially from anticipated results, performance, or achievements. We are under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events or otherwise.
CONTACT: Protea Biosciences Group, Inc. 955 Hartman Run Road Morgantown, WV 26507 USA Phone: 304.292.2226 Fax: 304.292.7101 Steve.email@example.com
Source:Protea Biosciences, Inc.